Literature DB >> 21406174

Netrin-4 delays colorectal cancer carcinomatosis by inhibiting tumor angiogenesis.

Clarisse Eveno1, Dong Broqueres-You, Jean-Guillaume Feron, Aurore Rampanou, Annemilaï Tijeras-Raballand, Stanislas Ropert, Laurence Leconte, Bernard I Levy, Marc Pocard.   

Abstract

A close relationship between tumor angiogenesis, growth, and carcinomatosis has been observed. Netrin-4 (NT-4) has been shown to regulate angiogenic responses. We aimed to examine the effects of NT-4 on colon tumor angiogenesis, growth, and carcinomatosis. We showed that NT-4 was expressed in human colon cancer cells (LS174). A 20-fold increase in NT-4 expression was stably induced by NT-4 pcDNA in LS174 cells. In vivo, a Matrigel angiogenesis assay showed that NT-4 overexpression altered vascular endothelial growth factor (VEGF)/basic fibroblast growth factor-induced angiogenesis. In nude mice with LS174 xenografts, NT-4 overexpression inhibited tumor angiogenesis and growth. In addition, these NT-4-involved inhibitory effects were associated with decreased tumor cell proliferation and increased tumor cell apoptosis. Using an orthotopic peritoneal carcinomatosis model, we demonstrated that NT-4 overexpression decreased colorectal cancer carcinomatosis. Moreover, carcinomatosis-related ascites formation was significantly decreased in mice transplanted with NT-4 LS174 cells versus control LS174 cells. The antiangiogenic activity of NT-4 was probably mediated by binding to its receptor neogenin. Netrin-4 had a direct effect on neither in vitro apoptosis and proliferation of cultured LS174 cells nor the VEGF-induced acute increase in vascular permeability in vivo. We propose that NT-4 overexpression decreases tumor growth and carcinomatosis, probably via an antiangiogenic effect, underlying the potential therapeutic interest in NT-4 in the treatment of colorectal cancer growth and carcinomatosis.
Copyright © 2011 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21406174      PMCID: PMC3078466          DOI: 10.1016/j.ajpath.2010.12.019

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  34 in total

Review 1.  Growth factor signaling by receptor tyrosine kinases.

Authors:  J Schlessinger; A Ullrich
Journal:  Neuron       Date:  1992-09       Impact factor: 17.173

2.  Vascular reactions to histamine, histamine-liberator and leukotaxine in the skin of guinea-pigs.

Authors:  A A MILES; E M MILES
Journal:  J Physiol       Date:  1952-10       Impact factor: 5.182

Review 3.  Eph receptors and ephrins in cancer: bidirectional signalling and beyond.

Authors:  Elena B Pasquale
Journal:  Nat Rev Cancer       Date:  2010-03       Impact factor: 60.716

4.  A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor.

Authors:  A Passaniti; R M Taylor; R Pili; Y Guo; P V Long; J A Haney; R R Pauly; D S Grant; G R Martin
Journal:  Lab Invest       Date:  1992-10       Impact factor: 5.662

Review 5.  Signal transduction by receptors with tyrosine kinase activity.

Authors:  A Ullrich; J Schlessinger
Journal:  Cell       Date:  1990-04-20       Impact factor: 41.582

6.  Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis.

Authors:  Jason D Wright; Andrea Hagemann; Janet S Rader; Dana Viviano; Randall K Gibb; Lori Norris; David G Mutch; Matthew A Powell
Journal:  Cancer       Date:  2006-07-01       Impact factor: 6.860

Review 7.  Tumor angiogenesis: therapeutic implications.

Authors:  J Folkman
Journal:  N Engl J Med       Date:  1971-11-18       Impact factor: 91.245

Review 8.  Antiangiogenesis drug design: multiple pathways targeting tumor vasculature.

Authors:  Haizhen Zhong; J Phillip Bowen
Journal:  Curr Med Chem       Date:  2006       Impact factor: 4.530

Review 9.  Progress and challenges in colorectal cancer screening and surveillance.

Authors:  David Lieberman
Journal:  Gastroenterology       Date:  2010-02-16       Impact factor: 22.682

10.  Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer.

Authors:  Rhonda L Harmon; Paul H Sugarbaker
Journal:  Int Semin Surg Oncol       Date:  2005-02-08
View more
  24 in total

1.  Lack of netrin-4 alters vascular remodeling in the retina.

Authors:  Sergio Crespo-Garcia; Nadine Reichhart; Jeffrey Wigdahl; Sergej Skosyrski; Norbert Kociok; Olaf Strauß; Antonia M Joussen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-08-26       Impact factor: 3.117

Review 2.  Exosomal Induction of Tumor Innervation.

Authors:  Paola D Vermeer
Journal:  Cancer Res       Date:  2019-05-14       Impact factor: 12.701

3.  Netrin-4 promotes glioblastoma cell proliferation through integrin β4 signaling.

Authors:  Yizhou Hu; Irene Ylivinkka; Ping Chen; Li Li; Sampsa Hautaniemi; Tuula A Nyman; Jorma Keski-Oja; Marko Hyytiäinen
Journal:  Neoplasia       Date:  2012-03       Impact factor: 5.715

4.  eQTL Colocalization Analyses Identify NTN4 as a Candidate Breast Cancer Risk Gene.

Authors:  Jonathan Beesley; Haran Sivakumaran; Mahdi Moradi Marjaneh; Wei Shi; Kristine M Hillman; Susanne Kaufmann; Nehal Hussein; Siddhartha Kar; Luize G Lima; Sunyoung Ham; Andreas Möller; Georgia Chenevix-Trench; Stacey L Edwards; Juliet D French
Journal:  Am J Hum Genet       Date:  2020-08-31       Impact factor: 11.025

5.  Netrin-1 promotes glioblastoma cell invasiveness and angiogenesis by multiple pathways including activation of RhoA, cathepsin B, and cAMP-response element-binding protein.

Authors:  Akio Shimizu; Hironao Nakayama; Priscilla Wang; Courtney König; Tomoshige Akino; Johanna Sandlund; Silvia Coma; Joseph E Italiano; Akiko Mammoto; Diane R Bielenberg; Michael Klagsbrun
Journal:  J Biol Chem       Date:  2012-11-29       Impact factor: 5.157

6.  Experimental pharmacokinetics evaluation of chemotherapy delivery by PIPAC for colon cancer: first evidence for efficacy.

Authors:  Clarisse Eveno; Aminata Haidara; Ibrahim Ali; Cynthia Pimpie; Massoud Mirshahi; Marc Pocard
Journal:  Pleura Peritoneum       Date:  2017-05-25

7.  Down-regulation of neogenin accelerated glioma progression through promoter Methylation and its overexpression in SHG-44 Induced Apoptosis.

Authors:  Xinmin Wu; Yunqian Li; Xilin Wan; Tabitha Mlowoka Kayira; Rangjuan Cao; Xingda Ju; Xiaojuan Zhu; Gang Zhao
Journal:  PLoS One       Date:  2012-05-29       Impact factor: 3.240

8.  Netrin-4 as a biomarker promotes cell proliferation and invasion in gastric cancer.

Authors:  Bin Lv; Chunhua Song; Lijun Wu; Qi Zhang; Daisen Hou; Ping Chen; Shunji Yu; Zhicheng Wang; Yiwei Chu; Jun Zhang; Dongqin Yang; Jie Liu
Journal:  Oncotarget       Date:  2015

9.  Identification of Novel Loci and New Risk Variant in Known Loci for Colorectal Cancer Risk in East Asians.

Authors:  Yingchang Lu; Sun-Seog Kweon; Qiuyin Cai; Chizu Tanikawa; Xiao-Ou Shu; Wei-Hua Jia; Yong-Bing Xiang; Jeroen R Huyghe; Tabitha A Harrison; Jeongseon Kim; Aesun Shin; Dong-Hyun Kim; Keitaro Matsuo; Sun Ha Jee; Xingyi Guo; Wanqing Wen; Jiajun Shi; Bingshan Li; Nan Wang; Min-Ho Shin; Hong-Lan Li; Zefang Ren; Jae Hwan Oh; Isao Oze; Yoon-Ok Ahn; Keum Ji Jung; Jing Gao; Yu-Tang Gao; Zhi-Zhong Pan; Yoichiro Kamatani; Andrew T Chan; Andrea Gsur; Jochen Hampe; Loic Le Marchand; Li Li; Annika Lindblom; Victor Moreno; Polly A Newcomb; Kenneth Offit; Paul D P Pharoah; Franzel J B van Duijnhoven; Bethany Van Guelpen; Pavel Vodicka; Stephanie J Weinstein; Alicja Wolk; Anna H Wu; Li Hsu; Yi-Xin Zeng; Jirong Long; Ulrike Peters; Koichi Matsuda; Wei Zheng
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-12-11       Impact factor: 4.254

10.  Netrin-4 promotes mural cell adhesion and recruitment to endothelial cells.

Authors:  Esma Lejmi; Ilyes Bouras; Serge Camelo; Marie Roumieux; Norbert Minet; Carole Leré-Déan; Tatyana Merkulova-Rainon; Gwennhael Autret; Catherine Vayssettes; Olivier Clement; Jean Plouët; Laurence Leconte
Journal:  Vasc Cell       Date:  2014-01-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.